At the German Cancer Congress 2016, held in Berlin, Germany, from 24 to 27 February 2016, Matthias Löhr, MD, PhD, from Karolinska Institutet, Stockholm, Sweden, discusses the value of the clinical use of next-generation sequencing for cancer management, including the accelerating trend towards evidence-based, multigene-driven personalised cancer therapeutics.
Introducing next-generation sequencing into the clinical care of cancer
14th June 2016
We are sorry that this content was not interesting for you!
Let us improve this content!
Tell us how we can improve this content?
Keep your finger on the pulseJoin Now
Elevating the Quality of Healthcare Globally